Tag: BurstDR

proclaim abbott

FDA approves low-dose spinal cord stimulator for chronic pain

Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...

Similar success rates for anatomic and targeted lead placement for spinal...

“Anatomical lead placement is a viable alternative to targeted lead placement for spinal cord stimulation,” concluded Jason E Pope, Evolve Restorative Center, Santa Rosa,...

“A failure in SCS is not a failure of the therapy...

Defining true success as “being able to decrease or even eliminate a patient’s dependency on oral opioids”, Corey W Hunter, founder of Ainsworth Institute...

Positive data for BurstDR spinal cord stimulation

New results from a multicentre study of Abbott’s BurstDR stimulation show that lower-energy, intermittent doses of BurstDR stimulation—known as “microdosing”—can provide pain relief that is...

Majority of radiculopathy patients prefer burst to conventional tonic stimulation

BurstDR stimulation confers a greater reduction in leg and back pain intensity on patients with failed back surgery syndrome that tonic stimulation does, a...

Preliminary results of the CRISP study suggest that intraoperative paresthesia mapping...

The CRISP study is looking at patients with chronic back pain. They were implanted with two leads; one using paraesthesia mapping (PM) and the...